




C18:1 (nmol/mL)




C18 (nmol/mL)




C16 (nmol/mL)




C16-OH (nmol/mL)




C14:1 (nmol/mL) *




C14 (nmol/mL)




C12 (nmol/mL)




C10 (nmol/mL)




C8 (nmol/mL)




C6 (nmol/mL)



C4 (nmol/mL)



C3 (nmol/mL)






Figure S1. Levels of various acylcarnitines and free carnitine in dried blood specimens of newborns. Infants with biallelic *ACADVL* variants and a VLCAD activity of <20% (A-1), 20%–40% (A-2), and >40% (A-3); infants heterozygous for *ACADVL* variants with a VLCAD activity of 20%–40% (B-1) and >40% (B-2); infants with a VLCAD activity of >70% without confirmation by *ACADVL* sequencing (C)

C0, free carnitine

* Levels of C14:1 are also shown on a logarithmic scale in Figure 1a.